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Abstract
Introduction Microcirculatory blood flow, and notably gut
perfusion, is important in the development of multiple organ
failure in septic shock. We compared the effects of dopexamine
and norepinephrine (noradrenaline) with those of epinephrine
(adrenaline) on gastric mucosal blood flow (GMBF) in patients
with septic shock. The effects of these drugs on oxidative stress
were also assessed.
Methods This was a prospective randomized study performed
in a surgical intensive care unit among adults fulfilling usual
criteria for septic shock. Systemic and pulmonary
hemodynamics, GMBF (laser-Doppler) and malondialdehyde
were assessed just before catecholamine infusion (T0), as soon
as mean arterial pressure (MAP) reached 70 to 80 mmHg (T1),
and 2 hours (T2) and 6 hours (T3) after T1. Drugs were titrated
from 0.2 µg kg-1 min-1 with 0.2 µg kg-1 min-1 increments every 3
minutes for epinephrine and norepinephrine, and from 0.5 µg kg-
1 min-1 with 0.5 µg kg-1 min-1 increments every 3 minutes for
dopexamine.
Results Twenty-two patients were included (10 receiving
epinephrine, 12 receiving dopexamine–norepinephrine). There
was no significant difference between groups on MAP at T0, T1,
T2, and T3. Heart rate and cardiac output increased significantly
more with epinephrine than with dopexamine–norepinephrine,
whereas. GMBF increased significantly more with dopexamine–
norepinephrine than with epinephrine between T1  and T3
(median values 106, 137, 133, and 165 versus 76, 91, 90, and
125 units of relative flux at T0, T1, T2 and T3, respectively).
Malondialdehyde similarly increased in both groups between T1
and T3.
Conclusion In septic shock, at doses that induced the same
effect on MAP, dopexamine–norepinephrine enhanced GMBF
more than epinephrine did. No difference was observed on
oxidative stress.
Introduction
In septic shock, when volume resuscitation fails to restore
mean arterial pressure (MAP), catecholamines such as
dopamine, dobutamine, epinephrine (adrenaline), or norepine-
phrine (noradrenaline) are used, either alone or in combination
[1-3]. Their effectiveness primarily reflects their cardiac and
vascular actions, but their ability to modulate the sepsis-
induced production of reactive oxygen species may also par-
ticipate [4]. Nonetheless, if they generally allow normalizing
MAP, they can leave some regional blood flows impaired,
especially hepatosplanchnic perfusion, which contributes to
multiple organ failure [5,6].
Dopexamine is a structural and synthetic analog of dopamine
that exerts systemic vasodilatation through the stimulation of
β2 adrenoceptors and peripheral DA1 and DA2 receptors, and
weak inotropic properties through the stimulation of β1 adren-
oceptors. This pharmacological profile could make the use of
GMBF = gastric mucosal blood flow; MAP = mean arterial pressure; SAPS II = Simplified Acute Physiology Score II; SOFA = Sequential Organ 
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dopexamine interesting in combination with norepinephrine to
improve both systemic hemodynamics and microcirculatory
blood flow, notably gut perfusion. Moreover, in rats, dopexam-
ine has been shown to exert a protective effect against the
reactive oxygen species generated by an intravenous adminis-
tration of xanthine followed by xanthine oxidase [7]. The main
objective of the present study was therefore to compare the
effects of the combination of dopexamine and norepinephrine
with those of epinephrine alone on gastric mucosal blood flow
(GMBF). The effects of these drugs on oxidative stress were
also assessed.
Materials and methods
Protocol and approval
The protocol was approved by the institutional review board
for human research of our hospital (Comité Consultatif de Pro-
tection des Personnes dans la Recherche Biomédicale de
Rennes) on September 5th 2001 (Reference number: 01/34-
355). The study was prospective, randomized, and open-
labeled, and was performed on two parallel groups. It was con-
ducted in a 21-bed surgical intensive care unit in a university
hospital. Informed consent was obtained from each patient or
next of kin.
Patients
Inclusion criteria
Adults aged over 18 years were included if they fulfilled the fol-
lowing:
(1) Evidence of infection.
(2) At least three of the following criteria: temperature more
than 38.0°C or less than 36.5°C, respiratory rate more than 20
breaths per minute or arterial pressure in CO2 (PaCO2) less
than 32 mmHg or mechanical ventilation, heart rate more than
90 beats per minute, white blood cell count more than 12,000
per mm3 or less than 4,000 per mm3.
(3) At least two of the following criteria: plasma lactate more
than 2 mmol per liter or unexplained metabolic acidosis (pH <
7.3), hypoxemia defined by arterial pressure in oxygen (PaO2)
less than 70 mmHg at room air or a ratio of PaO2 to fractional
inspired oxygen (FiO2) of less than 280 mmHg (or less than
200 mmHg if pneumonia was the source of sepsis) or a need
for mechanical ventilation, urine output less than 30 ml per
hour for at least 2 hours despite a fluid challenge of at least
500 ml, a platelet count of less than 100,000 per mm3 or a
decrease of 50% from a previous value or unexplained coagu-
lopathy (prothrombin time less than 60% and elevated fibrin
degradation products more than 10 µg per ml).
(4) Systolic blood pressure less than 90 mmHg despite an
optimal volume loading defined by a pulmonary capillary
wedge pressure more than 14 mmHg.
Non-inclusion criteria
Pregnant women and patients who had a history of esopha-
geal or gastric disease were not included; neither were
patients with a history of esophageal or gastric surgery.
Data collection at inclusion
The following data were recorded at inclusion: general charac-
teristics (age, weight, height, and sex); severity of illness
assessed by vital signs, Simplified Acute Physiology Score II
(SAPS II), and Sequential Organ Failure Assessment (SOFA)
score; and interventions including administered drugs, volume
of fluid infusion during the previous 24 hours, and mechanical
ventilation conditions. Moreover, blood samples were drawn
for hematological and biochemical analyses and blood cul-
tures, and specimens from the site of infection were collected
systematically.
Investigated variables
Systemic and pulmonary hemodynamics
All patients had an arterial catheter (Seldicath 4F 3874 13;
Plastimed Laboratories, Saint-Leu-La-Forêt, France) and a pul-
monary arterial catheter (ref. 831F35; Baxter Healthcare Cor-
poration, Irvine, CA, USA) connected to a monitor (7000/SC
9000XL; Siemens-Elema AB, Solna, Sweden) allowing meas-
urements of heart rate and arterial pressures (systolic and
diastolic systemic arterial pressures, right atrial pressure,
systolic and diastolic pulmonary arterial pressures, and pulmo-
nary capillary wedge pressure). Calibration was performed
with reference to the mild axillary line. Pulmonary capillary
wedge pressure was measured at the end of expiration. Car-
diac output was measured by thermodilution in triplicate with
10 ml of ice-cold (less than 5.0°C) 5% dextrose solution
injected asynchronously with the respiratory cycle. MAP and
mean pulmonary arterial pressure, stroke volume, and sys-
temic and pulmonary vascular resistances were calculated
from standard formulae.
Gastric mucosal blood flow
GMBF was assessed with a laser-Doppler flowmeter (Periflux
PF3; Perimed, Stockholm, Sweden) as described previously
[8,9]. In brief, the laser light is conducted and transmitted to
the tissue by an optic fiber (probe 324). Two signals are avail-
able for external recording. One signal is proportional to the
number and velocity of the red blood cells moving in the meas-
ured volume (about 1 mm3) and the other allows the determi-
nation of whether the optical probe is making adequate
contact with tissue surface. The flow value is expressed in
units of relative flux (perfusion units). Calibration was per-
formed against a standard latex solution before the start of
measurements, as recommended by the manufacturer. Then
the laser-Doppler probe was pushed through the noose into
the stomach, the position being checked with X-rays. All
patients had simultaneously a nasogastric tube suctioning at -
60 mmHg. The laser-Doppler signal was recorded on a com-
puter. Special care was taken to ensure persistent contactAvailable online http://ccforum.com/content/10/1/R32
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between the probe and the gastric mucosa. The ratio between
GMBF and cardiac output was calculated.
Blood gases and arterial lactate
Arterial and mixed venous blood gases were determined from
samples collected anaerobically in heparinized plastic
syringes through the arterial and distal port of the pulmonary
artery catheter, respectively. Samples were analyzed within 15
minutes by a co-oximeter (Abl 725; Radiometer, Copenhagen,
Denmark) to determine arterial and mixed venous oxygen ten-
sion and saturation, as well as arterial lactate concentration
(enzymatic dosage). Arterial and mixed venous oxygen con-
tent, oxygen delivery, and oxygen consumption were calcu-
lated from standard formulae.
Oxidative stress
Oxidative stress was assessed from plasma malondialdehyde
levels, as an index of lipid peroxidation induced by the genera-
tion of free radicals. Malondialdehyde concentrations were
estimated by a colorimetric test with thiobarbiturate [10]. After
precipitation of protein with a mixture of phosphotungstic acid
and sulfuric acid, the supernatant was incubated with thiobar-
biturate for one hour at 90°C. Thiobarbiturate-reactive sub-
stances were then extracted with n-butanol and the
absorbance was monitored at 535 nm. The concentrations
were calculated from a calibration curve obtained by the acid
hydrolysis of 1,1,3,3-tetramethoxypropane solution, generat-
ing standard concentrations of malondialdehyde. Standards
were then treated with thiobarbiturate reagent and extracted
with n-butanol in the same way as unknown samples. The nor-
mal value of malondialdehyde in healthy subjects was less than
4 µmol per liter.
Experimental protocol and treatments
As soon as inclusion criteria had been checked and informed
consent had been obtained, baseline measurements were per-
formed, including systemic and pulmonary hemodynamics and
GMBF, and blood samples were drawn (T0). Ventilator set-
tings were adapted for each patient so as to reach arterial oxy-
gen saturation above 90% and a plateau pressure lower than
30 cmH2O. Patients were then randomized to receive either
epinephrine alone or a combination of dopexamine and nore-
pinephrine. The unpredictability of randomization was guaran-
teed by two specific procedures: the randomization list,
generated with a computer, was equilibrated using unequal-
sized blocks and the randomization of a patient was performed
by an independent pharmacist. Study treatments were admin-
istered with an automatic syringe through the intermediate
Figure 1
Algorithm of doses adaptation in the two groups Algorithm of doses adaptation in the two groups. MAP, mean arterial pressure.Critical Care    Vol 10 No 1    Seguin et al.
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port of the pulmonary artery catheter. Drugs were titrated from
0.5 µg kg-1 min-1 with 0.5 µg kg-1 min-1 increments every 3 min-
utes for dopexamine and from 0.2 µg kg-1 min-1 with 0.2 µg kg-
1 min-1 increments every 3 minutes for norepinephrine and
epinephrine, until MAP reached 70 to 80 mmHg. If necessary,
dopexamine and norepinephrine doses were adjusted by
using cardiac output according to the algorithm in Figure 1.
When MAP was above 80 mmHg, the dose of norepinephrine
or epinephrine was adjusted to let MAP decrease to between
70 and 80 mmHg. Once the target MAP had been obtained,
the treatment was maintained at the same doses, and the
same measurements as at baseline were performed (T1). No
adjustment of fluid infusion or mechanical ventilation was
allowed during this first study period (namely between T0 and
T1). The same variables were measured two hours (T2) and six
hours (T3) later. During this second study period (that is,
between T1 and T3), fluid loading and doses of catecholamines
were adjusted to maintain a pulmonary capillary wedge pres-
sure of more than 14 mmHg and MAP between 70 and 80
mmHg, respectively.
Sample size
Sample size estimation was based on GMBF data from our
previous study, in which the standard deviation of GMBF was
160 units at inclusion [9]. In the actual protocol, 20 patients
were planned to be included so as to detect a difference
between the two groups of 240 units with a type I error of 5%
and a power of 95%.
Statistical analysis
Statistical analysis was performed with SAS statistical soft-
ware V8.02 (SAS Institute, Cary, NC, USA). Data are pre-
sented as means ± SD for normally distributed variables and
as medians (25th – 75th centiles) for non-normally distributed
variables. The homogeneity of pretreatment (T0) mean values
between groups was tested with Student's t  test or Wil-
coxon's rank sum test when needed. Comparisons of treat-
ment mean values between groups over the second study
period (that is, between T1 and T3) were performed with a two-
way (time, treatment) analysis of covariance (mixed model), the
analysis being adjusted on baseline values. In case of a signif-
icant time–treatment interaction, treatment effect was
assessed time by time by a one-way analysis of covariance
similarly adjusted on baseline values. For non-normally distrib-
uted variables a non-parametric repeated-measures analysis,
also adjusted on baseline values (mixed model), was per-
formed on ranked data. For all analyses, p < 0.05 was consid-
ered to be significant.
Results
A total of 22 patients were randomized (10 received epine-
phrine, and 12 received dopexamine–norepinephrine)
between March 25th 2002 and March 17th 2004. Two patients
(one in each group) were excluded from the analysis on the
main endpoint because of inadequate location of the laser-
Doppler probe, and two patients (one in each group) could not
be investigated at T3 because of the need for prompt surgical
management to control the source of sepsis.
General characteristics of study patients at inclusion
There was no significant difference between the groups in
age, weight, height, sex ratio, SAPS II, SOFA, volume of fluid
infusion during the previous 24 hours, and mechanical ventila-
tion conditions (Table 1). The origin of sepsis was essentially
peritonitis (six patients in the epinephrine group and nine
patients in the dopexamine–norepinephrine group). The infec-
tion was not microbiologically documented in one patient in
the epinephrine group and in two patients in the dopexamine–
norepinephrine group. Mortality rates at days 28 and 90 were
3/10 (30%) and 4/10 (40%), respectively, in the epinephrine
group, and 2/12 (17%) and 3/12 (25%), respectively, in the
dopexamine–norepinephrine group.
The median (25th – 75th centiles) delay between randomiza-
tion and stabilization of MAP at the target level was 60 minutes
(50 – 80 minutes) and 70 minutes (60 – 140 minutes) in the
epinephrine and dopexamine–norepinephrine groups, respec-
tively (p = 0.078). Median catecholamine doses (µg kg-1 min-
1) at the three times of investigation were 0.17 (0.14 to 0.19)
at T1, 0.19 (0.14 to 0.24) at T2 and 0.19 (0.18 to 0.21) at T3
for epinephrine, 0.51 (0.48 to 0.53) at T1, 0.51 (0.49 to 0.53)
at T2 and 0.51 (0.50 to 0.55) at T3 for dopexamine, and 0.20
(0.11 to 0.60) at T1, 0.20 (0.12 to 0.69) at T2 and 0.18 (0.11
to 0.74) at T3 for norepinephrine.
Table 1
General characteristics of study patients at inclusion
Parameter Epinephrine 
(n = 10)
Dopexamine–
norepinephrine 
(n = 12)
p
Age, years 67 ± 13 65 ± 10 0.797
Weight, kg 79 ± 15 77 ± 14 0.735
Height, cm 169 ± 9 168 ± 9 0.855
Sex ratio, M/F 8/2 9/3 1.00
SAPS II score 56 ± 17 52 ± 15 0.567
SOFA score 10 ± 4 10 ± 3 0.919
Fluid infusiona, ml 2,430 ± 980 2,521 ± 1,218 0.973
PaO2/FIO2, % 268 ± 103 191 ± 104 0.097
PEEPb, cmH2O6 7  ±  2
aThis corresponds to the amount of fluid infused during the previous 
24 hours; bthis applies to one and four patients in the epinephrine 
and dopexamine–norepinephrine groups, respectively.
Data are means ± SD or number of patients. FIO2, inspired oxygen 
fraction; PaO2, arterial pressure in oxygen; PEEP, positive end 
expiratory pressure; SAPS II, Simplified Acute Physiology Score II; 
SOFA, Sequential Organ Failure Assessment.Available online http://ccforum.com/content/10/1/R32
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Effects of treatments on systemic and pulmonary 
hemodynamics and oxygenation parameters
At baseline, there was no significant difference between the
two groups whichever variable was considered (Table 2).
There was also no significant difference in MAP between the
two groups at T1, T2, and T3. Heart rate and cardiac output
increased significantly more with epinephrine than with dopex-
amine–norepinephrine between T1 and T3 (+5%, p = 0.023 for
treatment effect, and +13%, p = 0.039, respectively). Simi-
larly, oxygen delivery and oxygen consumption increased sig-
nificantly more with epinephrine than with dopexamine–
norepinephrine between T1 and T3 (+17%, p = 0.009 for treat-
ment effect, and +34%, p = 0.001, respectively).
Effects of treatments on GMBF and on the ratio between 
GMBF and cardiac output
At baseline there was no significant difference in GMBF or in
the ratio between GMBF and cardiac output between the two
groups (Table 2). GMBF increased significantly more with
dopexamine–norepinephrine than with epinephrine (medians
Table 2
Effects of epinephrine and dopexamine–norepinephrine on hemodynamics, oxygenation parameters and gastric mucosal blood 
flow
Parameter Gro
up
T0 T1 T2 T3 p 
(time 
effect)
p 
(treatment 
effect)
p 
(interaction)
MAP, mmHg E 52 ± 7 81 ± 5 78 ± 4 87 ± 13 0.225 0.232 0.224
D–N 56 ± 8 79 ± 8 80 ± 9 80 ± 13
RAP, mmHg E 11 ± 3 13 ± 3 12 ± 3 10 ± 3 0.028 0.597 0.987
D–N 12 ± 3 13 ± 5 12 ± 3 10 ± 4
MPAP, mmHg E 23 ± 3 29 ± 6 29 ± 4 27 ± 5 0.289 0.141 0.453
D–N 27 ± 6 31 ± 8 28 ± 6 27 ± 7
PCWP, mmHg E 14 ± 4 15 ± 3 15 ± 4 14 ± 3 0.201 0.268 0.342
D–N 15 ± 4 16 ± 6 14 ± 4 12 ± 4
HR, beats/min E 94 ± 18 114 ± 24 113 ± 12 115 ± 14 0.991 0.023 0.699
D–N 102 ± 17 108 ± 21 109 ± 19 109 ± 18
SV, ml E 68 ± 30 92 ± 39 87 ± 36 81 ± 33 0.032 0.531 0.334
D–N 67 ± 21 81 ± 26 81 ± 18 78 ± 21
CO, l/min E 6.2 ± 2.4 10.1 ± 3.8 9.8 ± 4.1 9.2 ± 3.4 0.115 0.039 0.454
D–N 6.8 ± 2.2 8.6 ± 2.7 8.8 ± 2.1 8.4 ± 2.6
SVR, dyne.s/cm5 E 588 ± 188 635 ± 335 666 ± 400 803 ± 438 0.006 0.743 0.141
D–N 621 ± 412 722 ± 417 672 ± 275 746 ± 353
PVR, dyne.s/cm5 E 142 ± 84 122 ± 78 145 ± 103 143 ± 111 0.126 0.419 0.295
D–N 198 ± 207 175 ± 166 128 ± 40 164 ± 77
DO2, ml/min E 624 ± 246 1,142 ± 442 1,160 ± 518 1,163 ± 415 0.500 0.009 0.918
D–N 701 ± 220 967 ± 306 1,021 ± 275 968 ± 318
VO2, ml/min E 180 ± 46 275 ± 89 286 ± 53 250 ± 81 0.533 0.001 0.527
D–N 204 ± 60 178 ± 78 206 ± 95 219 ± 108
GMBF, pu E 76 (61–107) 91 (62–136) 90 (72–133) 125 (90–160) 0.084 0.048 0.913
D–N 106 (93–157) 137 (99–198) 133 (114–158) 165 (124–190)
GMBF/CO, pu l-1 min-1 E 18 (9–20) 11 (7–17) 15 (6–17) 15 (11–18) 0.128 0.015 0.686
D–N 15 (10–20) 17 (11–25) 15 (10–23) 18 (11–39)
Data are presented as means ± SD for normally distributed variables and as medians (25th to 75th centiles) for non-normally distributed variables. 
p values are those given by a two-way (time, treatment) analysis of covariance, the analysis being adjusted on baseline values (mixed model) for 
normally distributed variables or a non-parametric repeated-measures analysis, and also adjusted on baseline values (mixed model), performed on 
ranked data, for non-normally distributed variables. CO, cardiac output; D, dopexamine; DO2, oxygen delivery; E, epinephrine; GMBF, gastric 
mucosal blood flow; HR, heart rate; MAP, mean arterial pressure; MPAP, mean pulmonary arterial pressure; N, norepinephrine; PCWP, pulmonary 
capillary wedge pressure; pu, perfusion units; PVR, pulmonary vascular resistances; RAP, right atrial pressure; SV, stroke volume; SVR, systemic 
vascular resistances; VO2, oxygen consumption.Critical Care    Vol 10 No 1    Seguin et al.
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106, 137, 133, and 165 compared with 76, 91, 90, and 125
units of relative flux at T0, T1, T2, and T3, respectively; p =
0.048 for treatment effect; Figure 2, top). The ratio between
GMBF and cardiac output decreased with epinephrine,
whereas it did not change with dopexamine–norepinephrine
between T1 and T3 (p = 0.015 for treatment effect; Figure 2,
bottom).
Effects of treatments on arterial lactate concentration 
and oxidative stress
At baseline, there was no significant difference in arterial lac-
tate and malondialdehyde concentrations between the two
groups. Arterial lactate increased with epinephrine, whereas it
did not change with dopexamine–norepinephrine between T1
and T3 (p < 0.001 for treatment effect; Figure 3, top). Malond-
ialdehyde similarly increased in the two groups between T1
and T3 (p = 0.048 for time effect; p = 0.542 for treatment
effect; Figure 3, bottom).
Discussion
The key finding of our study was that in patients with septic
shock, at the same level of MAP, dopexamine–norepinephrine
enhanced GMBF more than epinephrine did.
With regard to systemic hemodynamics, epinephrine induced
greater heart rate, cardiac output, oxygen delivery, and oxygen
consumption than the combination of dopexamine and nore-
pinephrine. These effects express the well-known strong β1-
adrenergic stimulation induced by epinephrine [2] and the
more balanced cardiac and vascular effects induced by the
combination of dopexamine and norepinephrine. Epinephrine
also induced a significant increase in arterial lactate, as has
already been shown in patients with septic shock [9,11,12].
This effect may result from splanchnic hypoxia [12,13]. How-
ever, epinephrine could also increase arterial lactate inde-
pendently of a defect of cellular oxygenation by stimulation of
the skeletal muscle cell Na+, K+-ATPase, which accelerates
Figure 3
Evolution of arterial lactate and malondialdehyde concentrations Evolution of arterial lactate and malondialdehyde concentrations. T0, 
just before catecholamine infusion; T1, as soon as mean arterial pres-
sure reached 70 to 80 mmHg; T2, 2 hours after T1; T3, 6 hours after T1. 
Data are presented as boxplots.
Figure 2
Evolution of gastric mucosal blood flow (GMBF) and ratio between  GMBF and cardiac output Evolution of gastric mucosal blood flow (GMBF) and ratio between 
GMBF and cardiac output. T0, just before catecholamine infusion; T1, 
as soon as mean arterial pressure reached 70 to 80 mmHg; T2, 2 hours 
after T1; T3, 6 hours after T1. Data are presented as boxplots. CO, car-
diac output.Available online http://ccforum.com/content/10/1/R32
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aerobic glycolysis and consequently the production of lactate
[14].
The effect of catecholamines on the hepatosplanchnic per-
fusion of septic patients remains controversial, depending on
the method used to evaluate perfusion, the region studied
(extended versus limited area) and the severity of patients
(sepsis, severe sepsis, or septic shock). Indeed, dopexamine
infusion during sepsis and septic shock increased splanchnic
blood flow, but the fractional contribution of the regional blood
flow to cardiac output decreased or remained unchanged
[15,16]. In patients with septic shock, dopexamine alone or in
combination with another catecholamine either did not change
gastric mucosal pH [16,17] or increased it [18] but did not
modify the gastric mucosal–arterial pCO2 gradient [17]. When
using an original method to evaluate gastrointestinal mucosal
perfusion (reflectance spectrophotometry), dopexamine infu-
sion was shown to markedly improve the hemoglobin oxygen
saturation of gastric mucosa [17]. However, these results
were observed in uncontrolled studies. When patients with
septic shock previously treated by norepinephrine were rand-
omized to receive either dopexamine or dobutamine, the gas-
tric mucosal–arterial pCO2 gradient was improved similarly in
the two groups [19]. Similar conflicting results exist on the
effects of epinephrine on intestinal perfusion in sepsis. Epine-
phrine infusion was found to decrease splanchnic blood flow,
decrease gastric mucosal pH, and increase the gastric
mucosal–arterial pCO2 gradient [15]. However, two studies
found that GMBF, assessed as in our study by laser-Doppler
flowmetry, increased during epinephrine infusion in patients
with septic shock [8,9].
In the present study, both epinephrine and the combination of
dopexamine and norepinephrine durably increased GMBF, but
this effect was more pronounced with the combination of
dopexamine and norepinephrine. The ratio between GMBF
and cardiac output decreased during epinephrine infusion,
whereas it did not change during dopexamine–norepinephrine
infusion. Indeed, in comparison with dopexamine–norepine-
phrine, the increase in cardiac output allowed by epinephrine
was not totally distributed to the gastric mucosa, as shown by
a marked increase in estimated gastric mucosal resistance
(MAP over GMBF ratio = +41% between T0 and T1). In the
dopexamine–norepinephrine group, estimated gastric
mucosal resistance increased only slightly (+9% between T0
and T1), supporting the hypothesis of a dopexamine-induced
vasodilatation that counteracted the norepinephrine-induced
vasoconstriction. These results are in agreement with those of
experimental studies performed in septic rats demonstrating,
by videomicroscopy, an improvement in intestinal mucosal
blood flow during dopexamine infusion [20,21]. Our results
must be interpreted in the light of the limitation of the laser-
Doppler technique. Indeed, this technique does not take into
account the heterogeneity of microvascular blood flow (a
major characteristic of sepsis-induced microcirculatory disor-
ders), because this technique measures the average velocity
of all vessels comprised in the investigated volume [22,23].
Nevertheless, our results suggest that this technique is
adapted to assess flow variations in the investigated territory
under various pharmacological interventions.
The excessive production of reactive oxygen species during
sepsis may be involved in cellular damage [24,25]. A recent
study performed in critically ill patients showed a significant
increase in oxidative stress, as assessed by plasma concentra-
tions of thiobarbituric acid-reactant substances, both in
patients with systemic inflammatory response syndrome and
multiple organ failure and in non-survivors [26]. In rats, the
reactive oxygen species generated by an intravenous adminis-
tration of xanthine followed by xanthine oxidase induced a cir-
culatory failure with a survival rate of 20% [5]. When the
animals were pretreated by increasing doses of dopexamine,
survival was enhanced to 70%. In our study, the production of
malondialdehyde similarly increased in both groups and we
did not find any influence of dopexamine on the production of
reactive oxygen species.
Conclusion
In septic shock, at doses that induced the same effect on
MAP, dopexamine–norepinephrine enhanced GMBF more
than epinephrine did. No difference was observed on oxidative
stress. Our findings suggest that the combination of dopexam-
ine and norepinephrine could be an interesting alternative in
the treatment of the hemodynamic disturbances observed in
septic shock.
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•  In septic shock, at doses that induced the same effect 
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enhanced gastric mucosal blood flow more than epine-
phrine did.
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could be an interesting alternative in the treatment of 
the hemodynamic disturbances observed in septic 
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